Moreover, CXCL1 signalling in the tumour microenvironment is associated with tumour progression, tumour recurrence and drug resistance; [65] therefore, targeting CXCL1 signalling is a potential therapeutic approach for human BC. The gene discussed is CXCL1; the disease is breast cancer.